Lista de obras -

A Phase I study to assess the safety, tolerability and pharmacokinetic profile of boceprevir and sildenafil when dosed separately and together, in healthy male volunteers

artículo científico publicado en 2015

A case of iatrogenic adrenal suppression after co-administration of cobicistat and fluticasone nasal drops

artículo científico publicado en 2014

A simultaneous population pharmacokinetic analysis of rifampicin in Malawian adults and children.

artículo científico publicado en 2015

A validated method for quantification of efavirenz in dried blood spots using high-performance liquid chromatography-mass spectrometry

artículo científico publicado en 2015

Abacavir forms novel cross-linking abacavir protein adducts in patients.

artículo científico publicado en 2014

Adequacy of Rifampin Absorption after Jejunostomy Tube Administration.

artículo científico publicado en 2016

Breast milk pharmacokinetics of efavirenz and breastfed infants' exposure in genetically defined subgroups of mother-infant pairs: an observational study.

artículo científico publicado en 2015

CSF/plasma HIV-1 RNA discordance even at low levels is associated with up-regulation of host inflammatory mediators in CSF

artículo científico publicado en 2016

CYP2B618 is associated with nevirpine hypersensitivity independently of HLA-C04:01 in a Malawian HIV population.

artículo científico publicado en 2014

CYP3A4*22 (c.522-191 C>T; rs35599367) is associated with lopinavir pharmacokinetics in HIV-positive adults.

artículo científico publicado en 2014

Choice of antiretroviral drugs for continued treatment scale-up in a public health approach: what more do we need to know?

artículo científico publicado en 2016

Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications.

artículo científico publicado en 2016

Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study

artículo científico publicado en 2015

Darunavir pharmacokinetics throughout pregnancy and postpartum

artículo científico publicado en 2014

Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS.

artículo científico publicado en 2014

Differential Impact of Nevirapine on Artemether-Lumefantrine Pharmacokinetics in Individuals Stratified by CYP2B6 c.516G>T Genotypes

scientific article published on 21 February 2020

Discordant CSF/plasma HIV-1 RNA in patients with unexplained low-level viraemia.

artículo científico publicado en 2016

Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake

artículo científico publicado en 2015

Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis

artículo científico publicado en 2020

Dosing antiretroviral medication when crossing time zones: a review.

artículo científico

Drug Interactions between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine

scientific article published on 29 January 2019

Early experience of dolutegravir pharmacokinetics in pregnancy: high maternal levels and significant foetal exposure with twice-daily dosing

artículo científico publicado en 2016

Efavirenz and Metabolites in Cerebrospinal Fluid: Relationship with CYP2B6 c.516G→T Genotype and Perturbed Blood-Brain Barrier Due to Tuberculous Meningitis.

artículo científico publicado en 2016

Efavirenz- but not nevirapine-based antiretroviral therapy decreases exposure to the levonorgestrel released from a sub-dermal contraceptive implant

artículo científico publicado en 2014

Estimated generic prices for novel treatments for drug-resistant tuberculosis

artículo científico publicado en 2017

First experience of effectiveness and safety of bedaquiline for 18 months within an optimised regimen for XDR-TB.

artículo científico publicado en 2016

HIV associated neurocognitive disorders (HAND) in Malawian adults and effect on adherence to combination anti-retroviral therapy: a cross sectional study

artículo científico publicado en 2014

Hepatitis B virus sub-genotype A1 infection is characterized by high replication levels and rapid emergence of drug resistance in HIV-positive adults receiving first-line antiretroviral therapy in Malawi

artículo científico publicado en 2014

High prevalence and long duration of nervous system and psychiatric adverse drug reactions in Ugandan patients taking efavirenz 600 mg daily

artículo científico publicado en 2018

Hybrid stochastic framework predicts efficacy of prophylaxis against HIV: An example with different dolutegravir prophylaxis schemes

artículo científico publicado en 2018

Impact of polypharmacy on antiretroviral prescription in people living with HIV.

artículo científico publicado en 2016

Increasing use of 'party drugs' in people living with HIV on antiretrovirals: a concern for patient safety.

artículo científico publicado en 2015

Interaction of Rifampin and Darunavir-Ritonavir or Darunavir-Cobicistat In Vitro

artículo científico publicado en 2017

Is infant exposure to antiretroviral drugs during breastfeeding quantitatively important? A systematic review and meta-analysis of pharmacokinetic studies

artículo científico publicado en 2015

Key drug-drug interactions with direct-acting antiviral in HIV-HCV coinfection

artículo científico

Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment

artículo científico publicado en 2016

Managing potential drug-drug interactions between gastric acid-reducing agents and antiretroviral therapy: experience from a large HIV-positive cohort

artículo científico publicado en 2015

Mechanistic framework predicts drug-class specific utility of antiretrovirals for HIV prophylaxis

article

Minimum target prices for production of direct-acting antivirals and associated diagnostics to combat hepatitis C virus

artículo científico publicado en 2015

No pharmacokinetic interaction between raltegravir and amlodipine: importance for co-prescribing in ageing HIV-infected individuals

artículo científico publicado en 2014

Optimizing responses to drug safety signals in pregnancy: the example of dolutegravir and neural tube defects

scientific article published on 01 July 2019

Perceptions of Research Bronchoscopy in Malawian Adults with Pulmonary Tuberculosis: A Cross-Sectional Study

artículo científico publicado en 2016

Pharmacodynamic Modeling of Bacillary Elimination Rates and Detection of Bacterial Lipid Bodies in Sputum to Predict and Understand Outcomes in Treatment of Pulmonary Tuberculosis

artículo científico publicado en 2015

Pharmacogenetics of nevirapine excretion into breast milk and infants' exposure through breast milk versus postexposure prophylaxis.

artículo científico publicado en 2016

Pharmacogenetics of pregnancy-induced changes in efavirenz pharmacokinetics

artículo científico publicado en 2015

Pharmacokinetics (PK) of ethinylestradiol/levonorgestrel co-administered with atazanavir/cobicistat

artículo científico publicado en 2019

Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake Cessation.

artículo científico publicado en 2015

Population pharmacokinetic analysis of isoniazid, acetylisoniazid, and isonicotinic acid in healthy volunteers

artículo científico publicado en 2015

Population pharmacokinetics of rifampicin and 25-deacetyl-rifampicin in healthy Asian adults.

artículo científico publicado en 2015

Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial

artículo científico publicado en 2015

Pregnancy affects nevirapine pharmacokinetics: evidence from a CYP2B6 genotype-guided observational study.

artículo científico publicado en 2016

Prevalence and type of drug-drug interactions involving ART in patients attending a specialist HIV outpatient clinic in Kampala, Uganda

artículo científico publicado en 2015

Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate target site concentrations derived from their established human pharmacokinetics

artículo científico publicado en 2020

Removal of Dolutegravir by Hemodialysis in HIV-Infected Patients with End-Stage Renal Disease

artículo científico publicado en 2016

Reply to Banda et al., "Interpretation of Drug Interactions between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine"

scientific article published on 24 May 2019

Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study)

artículo científico publicado en 2019

Should the dose of tenofovir be reduced to 200-250 mg/day, when combined with protease inhibitors?

artículo científico publicado en 2014

Simulation of the impact of rifampicin on darunavir/ritonavir PK and dose adjustment strategies in HIV-infected patients: a population PK approach.

artículo científico publicado en 2014

Simulation of the impact of rifampicin on once-daily darunavir/ritonavir pharmacokinetics and dose adjustment strategies: a population pharmacokinetic approach.

artículo científico publicado en 2015

Telmisartan and Insulin Resistance in HIV (TAILoR): protocol for a dose-ranging phase II randomised open-labelled trial of telmisartan as a strategy for the reduction of insulin resistance in HIV-positive individuals on combination antiretroviral th

artículo científico publicado en 2015

Telmisartan to reduce insulin resistance in HIV-positive individuals on combination antiretroviral therapy: the TAILoR dose-ranging Phase II RCT

Tenofovir Disoproxil Fumarate Fails to Prevent HIV Acquisition or the Establishment of a Viral Reservoir: Two Case Reports

artículo científico publicado en 2016

The development and application of a novel LC-MS/MS method for the measurement of Dolutegravir, Elvitegravir and Cobicistat in human plasma.

artículo científico publicado en 2016

Therapeutic drug monitoring of atazanavir/ritonavir in pregnancy.

artículo científico publicado en 2014

Use of in vitro to in vivo extrapolation to predict the optimal strategy for patients switching from efavirenz to maraviroc or nevirapine.

artículo científico publicado en 2015

Validation and clinical application of a method to quantify efavirenz in cervicovaginal secretions from flocked swabs using liquid chromatography tandem mass spectrometry

artículo científico publicado en 2022

Validation and clinical application of a method to quantify nevirapine in dried blood spots and dried breast-milk spots.

artículo científico publicado en 2015

Vitamin D deficiency in Malawian adults with pulmonary tuberculosis: risk factors and treatment outcomes

artículo científico publicado en 2015

Lista de obras de

A Phase I study to assess the safety, tolerability and pharmacokinetic profile of boceprevir and sildenafil when dosed separately and together, in healthy male volunteers

A case of iatrogenic adrenal suppression after co-administration of cobicistat and fluticasone nasal drops

A simultaneous population pharmacokinetic analysis of rifampicin in Malawian adults and children.

A validated method for quantification of efavirenz in dried blood spots using high-performance liquid chromatography-mass spectrometry

Abacavir forms novel cross-linking abacavir protein adducts in patients.

Adequacy of Rifampin Absorption after Jejunostomy Tube Administration.

Breast milk pharmacokinetics of efavirenz and breastfed infants' exposure in genetically defined subgroups of mother-infant pairs: an observational study.

CSF/plasma HIV-1 RNA discordance even at low levels is associated with up-regulation of host inflammatory mediators in CSF

CYP2B6*18 is associated with nevirpine hypersensitivity independently of HLA-C*04:01 in a Malawian HIV population.

CYP3A4*22 (c.522-191 C>T; rs35599367) is associated with lopinavir pharmacokinetics in HIV-positive adults.

Choice of antiretroviral drugs for continued treatment scale-up in a public health approach: what more do we need to know?

Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications.

Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study

Darunavir pharmacokinetics throughout pregnancy and postpartum

Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS.

Differential Impact of Nevirapine on Artemether-Lumefantrine Pharmacokinetics in Individuals Stratified by CYP2B6 c.516G>T Genotypes

Discordant CSF/plasma HIV-1 RNA in patients with unexplained low-level viraemia.

Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake

Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis

Dosing antiretroviral medication when crossing time zones: a review.

Drug Interactions between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine

Early experience of dolutegravir pharmacokinetics in pregnancy: high maternal levels and significant foetal exposure with twice-daily dosing

Efavirenz and Metabolites in Cerebrospinal Fluid: Relationship with CYP2B6 c.516G→T Genotype and Perturbed Blood-Brain Barrier Due to Tuberculous Meningitis.

Efavirenz- but not nevirapine-based antiretroviral therapy decreases exposure to the levonorgestrel released from a sub-dermal contraceptive implant

Estimated generic prices for novel treatments for drug-resistant tuberculosis

First experience of effectiveness and safety of bedaquiline for 18 months within an optimised regimen for XDR-TB.

HIV associated neurocognitive disorders (HAND) in Malawian adults and effect on adherence to combination anti-retroviral therapy: a cross sectional study

Hepatitis B virus sub-genotype A1 infection is characterized by high replication levels and rapid emergence of drug resistance in HIV-positive adults receiving first-line antiretroviral therapy in Malawi

High prevalence and long duration of nervous system and psychiatric adverse drug reactions in Ugandan patients taking efavirenz 600 mg daily

Hybrid stochastic framework predicts efficacy of prophylaxis against HIV: An example with different dolutegravir prophylaxis schemes

Impact of polypharmacy on antiretroviral prescription in people living with HIV.

Increasing use of 'party drugs' in people living with HIV on antiretrovirals: a concern for patient safety.

Interaction of Rifampin and Darunavir-Ritonavir or Darunavir-Cobicistat In Vitro

Is infant exposure to antiretroviral drugs during breastfeeding quantitatively important? A systematic review and meta-analysis of pharmacokinetic studies

Key drug-drug interactions with direct-acting antiviral in HIV-HCV coinfection

Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment

Managing potential drug-drug interactions between gastric acid-reducing agents and antiretroviral therapy: experience from a large HIV-positive cohort

Mechanistic framework predicts drug-class specific utility of antiretrovirals for HIV prophylaxis

Minimum target prices for production of direct-acting antivirals and associated diagnostics to combat hepatitis C virus

No pharmacokinetic interaction between raltegravir and amlodipine: importance for co-prescribing in ageing HIV-infected individuals

Optimizing responses to drug safety signals in pregnancy: the example of dolutegravir and neural tube defects

Perceptions of Research Bronchoscopy in Malawian Adults with Pulmonary Tuberculosis: A Cross-Sectional Study

Pharmacodynamic Modeling of Bacillary Elimination Rates and Detection of Bacterial Lipid Bodies in Sputum to Predict and Understand Outcomes in Treatment of Pulmonary Tuberculosis

Pharmacogenetics of nevirapine excretion into breast milk and infants' exposure through breast milk versus postexposure prophylaxis.

Pharmacogenetics of pregnancy-induced changes in efavirenz pharmacokinetics

Pharmacokinetics (PK) of ethinylestradiol/levonorgestrel co-administered with atazanavir/cobicistat

Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake Cessation.

Population pharmacokinetic analysis of isoniazid, acetylisoniazid, and isonicotinic acid in healthy volunteers

Population pharmacokinetics of rifampicin and 25-deacetyl-rifampicin in healthy Asian adults.

Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial

Pregnancy affects nevirapine pharmacokinetics: evidence from a CYP2B6 genotype-guided observational study.

Prevalence and type of drug-drug interactions involving ART in patients attending a specialist HIV outpatient clinic in Kampala, Uganda

Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate target site concentrations derived from their established human pharmacokinetics

Removal of Dolutegravir by Hemodialysis in HIV-Infected Patients with End-Stage Renal Disease

Reply to Banda et al., "Interpretation of Drug Interactions between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine"

Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study)

Should the dose of tenofovir be reduced to 200-250 mg/day, when combined with protease inhibitors?

Simulation of the impact of rifampicin on darunavir/ritonavir PK and dose adjustment strategies in HIV-infected patients: a population PK approach.

Simulation of the impact of rifampicin on once-daily darunavir/ritonavir pharmacokinetics and dose adjustment strategies: a population pharmacokinetic approach.

Telmisartan and Insulin Resistance in HIV (TAILoR): protocol for a dose-ranging phase II randomised open-labelled trial of telmisartan as a strategy for the reduction of insulin resistance in HIV-positive individuals on combination antiretroviral th

Telmisartan to reduce insulin resistance in HIV-positive individuals on combination antiretroviral therapy: the TAILoR dose-ranging Phase II RCT

Tenofovir Disoproxil Fumarate Fails to Prevent HIV Acquisition or the Establishment of a Viral Reservoir: Two Case Reports

The development and application of a novel LC-MS/MS method for the measurement of Dolutegravir, Elvitegravir and Cobicistat in human plasma.

Therapeutic drug monitoring of atazanavir/ritonavir in pregnancy.

Use of in vitro to in vivo extrapolation to predict the optimal strategy for patients switching from efavirenz to maraviroc or nevirapine.

Validation and clinical application of a method to quantify efavirenz in cervicovaginal secretions from flocked swabs using liquid chromatography tandem mass spectrometry

Validation and clinical application of a method to quantify nevirapine in dried blood spots and dried breast-milk spots.

Vitamin D deficiency in Malawian adults with pulmonary tuberculosis: risk factors and treatment outcomes

CYP2B618 is associated with nevirpine hypersensitivity independently of HLA-C04:01 in a Malawian HIV population.